ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Bio Usawa Takes Strategic Step into Europe with New Subsidiary in Frankfurt, Germany

KIGALI, Rwanda and FRANKFURT, Germany and SAN FRANCISCO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology Ltd (Rwanda) proudly announces the establishment of its new European subsidiary, Bio Usawa Biotech Europe GmbH, headquartered in Frankfurt, Germany.

This strategic development marks a significant milestone in Bio Usawa’s mission to bridge African innovation with international research, regulatory, and commercial networks.

Bio Usawa selected Frankfurt for its reputation as one of Europe’s foremost life sciences and pharmaceutical hubs, providing access to leading scientific expertise, strong global partnerships, and a vibrant biotechnology ecosystem.

The new European subsidiary will strengthen Bio Usawa’s ability to collaborate with institutions and companies that share its vision of developing and delivering advanced biologic therapies that reach patients faster and more affordably.

“Establishing Bio Usawa Biotech Europe GmbH represents an important step in Bio Usawa’s journey,” said Dr. Menghis Bairu, CEO and President of Bio Usawa. “We are building a company that connects continents – advancing science from Africa to the world and bringing global expertise back to Africa. Our aim is to develop biotechnology solutions that are innovative, high-quality, and accessible to all.”

The Frankfurt-based entity will serve as Bio Usawa’s European anchor for partnerships, regulatory engagement, and scientific collaboration, reinforcing the company’s role as a bridge between Africa and the global biotechnology community.

As part of its broader vision, Bio Usawa is helping transform Africa’s “brain drain” into “brain gain” — attracting talented scientists and innovators from Africa and friends of Africa across the diaspora who are eager to contribute to the continent’s rapidly evolving biotechnology landscape. By fostering cross-continental collaboration and knowledge exchange, Bio Usawa is demonstrating that scientific excellence transcends borders.

About Bio Usawa, Inc

Bio Usawa is Rwanda’s pioneering biotech company that is dedicated to developing, manufacturing, and commercializing high-quality, affordable biosimilars for patients in Africa. Through partnerships with governments, research institutions, and healthcare providers, Bio Usawa is advancing biotechnology innovation in Africa, by Africans, for Africa – and beyond.

Media Contact:

Daniel Levine
Levine Media Group
+1 510-280-5405
danny@levinemediagroup.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.27
-1.29 (-0.58%)
AAPL  271.84
-2.77 (-1.01%)
AMD  198.11
-11.06 (-5.29%)
BAC  54.55
-0.26 (-0.47%)
GOOG  298.05
-9.68 (-3.15%)
META  649.50
-7.65 (-1.16%)
MSFT  476.12
-0.27 (-0.06%)
NVDA  170.94
-6.78 (-3.81%)
ORCL  178.46
-10.19 (-5.40%)
TSLA  467.26
-22.62 (-4.62%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.